Tag: CaPre

December 31, 2018

Acasti Pharma Announces Data on TRILOGY Phase 3 Trials of CaPre in Patients

Acasti Pharma (NASDAQ:ACST;TSXV:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre (omega-3...
October 4, 2018

Acasti Pharma Announces Pricing of $16.6 Million Underwritten Public Offering of Common Shares

Acasti Pharma (NASDAQ:ACST;TSXV:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre (omega-3...
February 14, 2018

Acasti Pharma Reports Third Quarter FY 2018 Financial Results

Acasti Pharma (NASDAQ:ACST) a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3...
January 22, 2018

Acasti Pharma Announces the Closing of Over-Allotment Option for its Public Offering of Common Shares

Acasti Pharma (NASDAQ:ACST) a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® for...
January 11, 2018

Biotech Showcase Conference: Notes from the Floor, Day Three

INN brings the latest from the last day of the Biotech Showcase conference in San Francisco.
January 8, 2018

Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest Under Debentures

Acasti Pharma (NASDAQ:ACST; TSXV:ACST) has announced that in accordance with the terms of the outstanding convertible debentures in the total...
November 22, 2017

Acasti Pharma Clarifies Terms of New Partnership

Acasti Pharma provided shareholders with a clarification on its proposed partnership with an undisclosed Chinese pharmaceutical company.